Stocks and Investing Stocks and Investing
Tue, March 6, 2018
Mon, March 5, 2018

Jason McCarthy Maintained (VRTX) at Strong Buy with Increased Target to $200 on, Mar 5th, 2018


Published on 2024-10-26 03:35:12 - WOPRAI, Jason McCarthy
  Print publication without navigation


Jason McCarthy of Maxim Group, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $195 to $200 on, Mar 5th, 2018.

Jason has made no other calls on VRTX in the last 4 months.



There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 0 agree with Jason's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Jason


  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $196 on, Tuesday, February 13th, 2018
  • Liisa Bayko of "JMP Securities" Maintained at Buy with Increased Target to $211 on, Tuesday, February 13th, 2018
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $200 on, Friday, February 2nd, 2018
  • Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $197 on, Thursday, February 1st, 2018
  • Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $191 on, Thursday, February 1st, 2018
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $200 on, Thursday, February 1st, 2018
Contributing Sources